Immediate Impact
58 standout
Citing Papers
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease
2025 Standout
Works of Jessica A. Hellyer being referenced
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
2019
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jessica A. Hellyer | 312 | 306 | 140 | 226 | 29 | 715 | |
| Matthew G. Tutton | 347 | 112 | 170 | 353 | 19 | 810 | |
| Shirin Ardeshir‐Rouhani‐Fard | 189 | 129 | 29 | 117 | 31 | 712 | |
| J.B. Pracyk | 123 | 179 | 50 | 382 | 21 | 847 | |
| Hilal Oğuz | 344 | 102 | 160 | 343 | 45 | 788 | |
| Benjamin R. Thomson | 160 | 76 | 39 | 375 | 27 | 784 | |
| Yen‐Rei Yu | 137 | 209 | 60 | 313 | 25 | 676 | |
| Victoria Wang | 234 | 126 | 152 | 373 | 43 | 777 | |
| Xiaolin Wang | 256 | 145 | 194 | 289 | 37 | 826 | |
| Xiang Qu | 159 | 114 | 322 | 310 | 48 | 709 | |
| Takuya Akashi | 305 | 125 | 80 | 202 | 30 | 734 |
All Works
Login with ORCID to disown or claim papers
Loading papers...